Researcher
Hans Prenen
- Keywords (University of Antwerp):Medicine
- Disciplines (University of Antwerp):Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention, Cancer therapy
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Hans Prenen (KU Leuven)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Oct 2020 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From12 Jul 2017 → 30 Apr 2018 - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 23 Jul 2017 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 2009 → 31 Dec 2011
Projects
1 - 2 of 2
- Development of an image-based multiparametric drug response signature to predict clinical therapy response in cancer patients from ex vivo tumoroid screenings.From1 Oct 2022 → TodayFunding: BOF - doctoral mandates
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
Publications
31 - 40 of 150
- Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer(2021)
Authors: Christopher G.C.A. Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Blair McLaren, Noelyn Anne Hung, Katriona Clarke, Tsu-Yi Chao, Ming-Shen Dai, et al.
Pages: 4670 - 4680 - Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies(2021)
Authors: Maxim Le Compte, Niels Komen, Marc Peeters, Hans Prenen, Evelien Smits, Christophe Deben, Michiel de Maat
- Kankergeassocieerde fibroblasten dragen bij tot therapieresistentie in long- en pancreaskanker(2021)
Authors: Delphine Quatannens, Hans Prenen
Pages: 32 - 36 - Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy(2021)
Authors: D. Vervloet, Constantijn Franssen, Lieselot Croes, F. Gremonprez, Hans Prenen, Marc Peeters, Christof Vulsteke
- The role of neoadjuvant chemotherapy in locally advanced colon cancer(2021)
Authors: Amy Body, Hans Prenen, Sarah Latham, Marissa Lam, Samuel Tipping-Smith, Ajay Raghunath, Eva Segelov
Pages: 2567 - 2579 - Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer(2021)
Authors: Delphine Quatannens, Sara Zanivan, Christophe Deben, Jonas Van Audenaerde, Evelien Smits, An Wouters, Filip Lardon, Geert Roeyen, Yannick Verhoeven, Timon Vandamme, et al.
- Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma(2021)
Authors: Shruti G. Dighe, Jianhong Chen, Li Yan, Qianchuan He, Puya Gharahkhani, Lynn Onstad, David M. Levine, Claire Palles, Weimin Ye, Marilie D. Gammon, et al.
Pages: 369 - 377 - Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer(2021)
Authors: Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, et al.
Pages: 1 - 9 - The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer(2021)
Authors: Michael Z. Liao, Hans Prenen, Sandeep Dutta, Vijay V. Upreti
Pages: 665 - 672 - Immunoglobin G/total antibody testing for SARS-CoV-2(2021)
Authors: Peter Van Dam, Manon Huizing, Ella Roelant, An Hotterbeekx, Fien De Winter, Samir Kumar-Singh, Pieter Moons, Zainab Amajoud, Christof Vulsteke, Lieselot Croes, et al.
Pages: 328 - 339